Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cannabis Science International Holding has signed an agreement with the Institute for Research, Hospitalization and Health Care on Ageing (INRCA) in Italy.
Subscribe to our email newsletter
The deal provides toxicity and efficacy studies of cannabinoid formulations carried out in animal models for neurobehavioral diseases including sleep disorders.
The company said that the first formulation in the series of neurobehavioral disorder-targeted products is in the pre-clinical development stage.
INRCA researcher in charge of the pre-clinical study Dr Marco Malavolta said: "We are excited to be initiating research on cannabinoids with Cannabis Science; the preliminary results are promising."
Malavolta is currently conducting research with Dr Mauro Provinciali on nutritional factors that affect cellular aging, a process also called as cellular senescence.
They are undergoing their research at the Nutrition and Ageing Centre of the Scientific and Technological Pole of INRCA, a department with a long historical background in multiple aspects of gerontology research.
Cannabis Science director and president of European Operations Mario Lap said: "We appreciate the scientific input from the INRCA colleagues in Italy and hope that we will be able to transition into clinical this program next year."